Biophytis shares and BSA trading is suspended pending a new press release
Paris (France), Cambridge (Massachusetts, USA), September 30, 2020, 8.00 a.m.
CEST - BIOPHYTIS (Euronext Growth Paris) asked Euronext Paris to suspend the
trading of its shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code :
FR0013507290-BPSBS) as from today 30th September 2020, pending the publication
of a new press release.
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, including
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The
company plans to start the clinical development (MYODA) in H2 2020.
Sarconeos (BIO101) is also being developed as a treatment for patients with
COVID-19 related respiratory failure in a Phase 2/3 clinical study (COVA) in
the United States, Europe and Latin America.
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO